Skip to main content

Cold

3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Ache Laboratorios Farmaceuticos
2 programs
2
Desloratadine + Phenylephrine + IbuprofenPhase 3Small Molecule
Desloratadine+Phenylephrine+IbuprofenPhase 3Small Molecule1 trial
Active Trials
NCT02904304Suspended150Est. Sep 2021
Biocorp
BiocorpFrance - Issoire
1 program
1
Regan TangjiangPhase 21 trial
Active Trials
NCT03089138Unknown120Est. Mar 2018
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Atrovent®PHASE_41 trial
Active Trials
NCT02238210Completed230

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimAtrovent®
Ache Laboratorios FarmaceuticosDesloratadine+Phenylephrine+Ibuprofen
BiocorpRegan Tangjiang

Clinical Trials (3)

Total enrollment: 500 patients across 3 trials

NCT02238210Boehringer IngelheimAtrovent®

Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy

Start: Dec 2002230 patients
Phase 4Completed
NCT02904304Ache Laboratorios FarmaceuticosDesloratadine+Phenylephrine+Ibuprofen

Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

Start: Dec 2020Est. completion: Sep 2021150 patients
Phase 3Suspended
NCT03089138BiocorpRegan Tangjiang

Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome

Start: Mar 2017Est. completion: Mar 2018120 patients
Phase 2Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.